Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens.
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge.
The considerably large acquisition puts Cybin in the limelight with credibility status in ongoing and future work - see Cybin’s recent acquisition announcement of DMT therapeutics developer Small Pharma DMTTF.
Blake Mycoskie On His $100M Pledge To Psychedelics Research
Following a sound pledge of $100 million for psychedelics research, billionaire Blake Mycoskie has updated on how his funding agenda -representing around 25% of his wealth- will unfold.
Mycoskie says he is planning to “give $5 million a year for the rest of the time, until the $100 million runs out,” a yearly sum that “feels right, because the industry still feels nascent.”
That could change in the presence of “a huge opportunity” or in the need of “a huge campaign push.” Although he understands other donors are waiting for further regulatory and scientific success, his personal standpoint is that those aren’t needed in view of solid works authored by Johns Hopkins and New York University, among others.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens.
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge.
The considerably large acquisition puts Cybin in the limelight with credibility status in ongoing and future work - see Cybin’s recent acquisition announcement of DMT therapeutics developer Small Pharma DMTTF.
Blake Mycoskie On His $100M Pledge To Psychedelics Research
Following a sound pledge of $100 million for psychedelics research, billionaire Blake Mycoskie has updated on how his funding agenda -representing around 25% of his wealth- will unfold.
Mycoskie says he is planning to “give $5 million a year for the rest of the time, until the $100 million runs out,” a yearly sum that “feels right, because the industry still feels nascent.”
That could change in the presence of “a huge opportunity” or in the need of “a huge campaign push.” Although he understands other donors are waiting for further regulatory and scientific success, his personal standpoint is that those aren’t needed in view of solid works authored by Johns Hopkins and New York University, among others.
Comment:
Comment:
Comment:
Comment: